Postdoctoral Scientist Acute/Critical Care Disorders (m/f)


Your tasks and responsibilities

 

Bayer is one of the leading research-based pharmaceutical companies worldwide. Its pharmaceutical business is located in Berlin and Wuppertal, Germany, where more than 1.000 scientists discover new medicines with the goal to improve the life of patients. To strengthen this research, we are offering a postdoctoral position in the department of Cardiovascular Research:

 

• Be part of a team that identifies and characterizes novel treatment options for patients with acute/critical care

  diseases incl. acute lung injuries, acute kidney injuries, systemic inflammatory reaction syndromes, and disseminated

  intravascular coagulation

• Work in a research laboratory and plan, execute and evaluate in vitro and in vivo pharmacology studies in the field of

  critical care diseases

• Participate in interdisciplinary teams and projects from target identification, target validation to optimization of

  substances and preclinical studies

• Drive and implement change for improving everyday work

 

Who you are

 

• PhD in biology, biochemistry, molecular biology or genetics, alternatively in medical science or pharmacy

• Interested in the field of critical care diseases

• Proven track record of successful publications of outstanding research in high impact journals

• Interested in leading scientific staff and working in interdisciplinary teams

• Excellent organizational skills, sense of responsibility, creative and flexible thinking

• Curiosity and passion for research

• Effective communication skills and fluent command of English, both verbal and written

 

This is a fixed-term contract for two years.

 

Your application

Are you looking for a new challenge where you can show your passion for innovation? Are you interested in working as part of a global team to improve people’s lives? Then send us your online application including cover letter, CV and references.
Refer to gradeview.io in your application

Info

09.08.2018
Direct entry
Research & development
Earliest entry: ab sofort